메뉴 건너뛰기




Volumn 5, Issue 4, 2010, Pages 500-512

Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics

Author keywords

Antitumor agents; Cancer; Hedgehog; Signal transduction; Smoothened

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPAMINE; DASATINIB; ETOPOSIDE; GANT 58; GANT 61; GDC 0449; HEDGEHOG PROTEIN INHIBITOR; IPI 269609; IPI 926; JK 184; LDE 225; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; NILOTINIB; NMDA 298 1; PF 04449913; PHTHALAZINE DERIVATIVE; PHYSALIN B; PHYSALIN F; ROBOTNIKININ; SANT 19; SANT 74; SANT 75; SMOOTHENED PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG; XL 139;

EID: 77950647110     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000011     Document Type: Review
Times cited : (152)

References (96)
  • 1
  • 38
    • 77950653227 scopus 로고    scopus 로고
    • L. Rubin, O. M. Guicherit, S. Price, E. A. Boyd (Curis Inc.) WO200311219A2 2003
    • L. Rubin, O. M. Guicherit, S. Price, E. A. Boyd, (Curis, Inc.), WO200311219A2, 2003.
  • 45
    • 77950633311 scopus 로고    scopus 로고
    • P. A. Hipskind,T. Takakuwa, (Eli Lilly & Co.), WO2009134574A2, 2009
    • P. A. Hipskind, T. Takakuwa, (Eli Lilly & Co.), WO2009134574A2, 2009.
  • 56
    • 77950648309 scopus 로고    scopus 로고
    • R.J. Austin, J. Kaizerman, B. Lucas, D. L McMinn, J. Powers (Amgen Inc.) WO2009002469A1 2009
    • R.J. Austin, J. Kaizerman, B. Lucas, D. L McMinn, J. Powers, (Amgen, Inc.), WO2009002469A1, 2009.
  • 57
    • 77950682065 scopus 로고    scopus 로고
    • J. M. Balkovec, R. Thieringer, S. T. Waldell (Merck & Co. Inc.) US2008262051A1 2008
    • J. M. Balkovec, R. Thieringer, S. T. Waldell, (Merck & Co., Inc.), US2008262051A1, 2008.
  • 62
    • 77950658099 scopus 로고    scopus 로고
    • Curis press release, June 8 2005 July 11 2006 http://phx.corporate-ir. net/phoe-nix.zhtml?c=123198&p=irol-newsArticle&ID=881050&highlight=
    • Curis press release, June 8, 2005, http://phx.corporate-ir.net/phoe-nix. zhtml?c=123198&p=irol-newsArticle-print&ID=718277&high-light=.Curis press release, July 11, 2006, http://phx.corporate-ir.net/phoe-nix.zhtml?c= 123198&p=irol-newsArticle&ID=881050&highlight=.
  • 64
    • 77950637672 scopus 로고    scopus 로고
    • A. D. Baxter, E. A. Boyd, O. M. Guichert, S. Price, L. D. Rubin (Curis Inc.) WO2001019800A2 2001
    • A. D. Baxter, E. A. Boyd, O. M. Guichert, S. Price, L. D. Rubin, (Curis, Inc.), WO2001019800A2, 2001.
  • 67
    • 77950650618 scopus 로고    scopus 로고
    • A study evaluating the efficacy and safety of GDC-0449 (Hedgehog pathway inhibitor) in patients with advanced basal cell carcinoma
    • A study evaluating the efficacy and safety of GDC-0449 (Hedgehog pathway inhibitor) in patients with advanced basal cell carcinoma, http:// clinicaltrials.gov/ct2/show/NCT00833417?term=GDC-0449&rank=1.
  • 68
    • 77950656035 scopus 로고    scopus 로고
    • A study of GDC-0449 (Hedgehog pathway inhibitor) with concurrent chemotherapy and bevacizumab as first-line therapy for metastatic col-orectal cancer
    • A study of GDC-0449 (Hedgehog pathway inhibitor) with concurrent chemotherapy and bevacizumab as first-line therapy for metastatic col-orectal cancer, http://clinicaltrials.gov/ct2/show/NCT00636610?term=GDC-0449&rank=4.
  • 69
    • 77950640999 scopus 로고    scopus 로고
    • A study of GDC-0449 (Hedgehog pathway inhibitor) as maintenance therapy in patients with ovarian cancer in a second or third complete remission
    • A study of GDC-0449 (Hedgehog pathway inhibitor) as maintenance therapy in patients with ovarian cancer in a second or third complete remission, http://clinicaltrials.gov/ct2/show/NCT00739661?term=GDC-0449&rank=5.
  • 70
    • 77950633023 scopus 로고    scopus 로고
    • GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment
    • GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment, http://clinicaltrials.-gov/ ct2/show/NCT00822458?term=GDC-0449&rank=2.
  • 72
    • 77950674110 scopus 로고    scopus 로고
    • A phase I study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies
    • A phase I study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies, http://clinicaltrials.gov/ct2/show/NCT00761696?term= ipi-926&rank=1.
  • 73
    • 77950687864 scopus 로고    scopus 로고
    • W. Gao, J. Jiang, Y. Wan, D. Cheng, D. Han, X. Wu, S. Pan (IRM LLC) WO 2007 131201, 2007
    • W. Gao, J. Jiang, Y. Wan, D. Cheng, D. Han, X. Wu, S. Pan, (IRM, LLC), WO2007131201, 2007.
  • 74
    • 77950647397 scopus 로고    scopus 로고
    • C. Dierks, M. Warmuth, X. Wu (IRM LLC) WO 2008 154259, 2008
    • C. Dierks, M. Warmuth, X. Wu, (IRM, LLC), WO2008154259, 2008.
  • 75
    • 77950669566 scopus 로고    scopus 로고
    • D. Cheng, D. Han, W. Gao, J. Jiang, S. Pan, Y. Wan (IRM LLC) WO 2008 014291, 2008
    • D. Cheng, D. Han, W. Gao, J. Jiang, S. Pan, Y. Wan, (IRM, LLC), WO2008014291, 2008.
  • 76
    • 77950663881 scopus 로고    scopus 로고
    • Dose finding and safety of oral LDE225 in patients with advanced solid tumors
    • Dose finding and safety of oral LDE225 in patients with advanced solid tumors, http://clinicaltrials.gov/ct2/show/NCT00880308.
  • 77
    • 77950655755 scopus 로고    scopus 로고
    • A trial to evaluate the safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on skin basal cell carcinomas in Gorlin's syndrome patients
    • A trial to evaluate the safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on skin basal cell carcinomas in Gorlin's syndrome patients, http://clinicaltrials.gov/ct2/show/NCT00961896.
  • 78
    • 77950664183 scopus 로고    scopus 로고
    • S. Bahceci, W. Bajjalieh, J. Chen, S. Epshteyn,T. P. Forsyth, T. P. Huynh, B. G. Kim, J. W. Leahy, M. S. Lee, G. L. Lewis,M. B. Mac,G. Mann, C. K. Marlowe, B. H. Ridgway, J. C. Sangalang, X. Shi,C. S. Takeuchi,Y. Wang (Exelixis Inc.) WO2008112913 2008
    • S. Bahceci, W. Bajjalieh, J. Chen, S. Epshteyn, T. P. Forsyth, T. P. Huynh, B. G. Kim, J. W. Leahy, M. S. Lee, G. L. Lewis, M. B. Mac, G. Mann, C. K. Marlowe, B. H. Ridgway, J. C. Sangalang, X. Shi, C. S. Takeuchi, Y. Wang, (Exelixis, Inc.), WO2008112913, 2008.
  • 80
    • 77950688350 scopus 로고    scopus 로고
    • M. J. Munchhof, L. A. Reiter, A. Shavnya,C. S. Jones,Q. Li R. G. Linde (Pfizer Products Inc.) WO2008075196 2008
    • M. J. Munchhof, L. A. Reiter, A. Shavnya, C. S. Jones, Q. Li, R. G. Linde, (Pfizer Products, Inc.), WO2008075196, 2008.
  • 81
    • 77950684479 scopus 로고    scopus 로고
    • M. J. Munchof, L. A. Reiter, S. D. La Greca C. S. Jones, Q. Li (Pfizer Products Inc.) US20090005416 2009
    • M. J. Munchof, L. A. Reiter, S. D. La Greca, C. S. Jones, Q. Li, (Pfizer Products, Inc.), US20090005416, 2009.
  • 82
    • 77950680925 scopus 로고    scopus 로고
    • A study of PF-04449913 in select hematologic malignancies or with da-satinib in chronic myeloid leukemia (CML)
    • A study of PF-04449913 in select hematologic malignancies or with da-satinib in chronic myeloid leukemia (CML), http://clinicaltrials.gov/ct2/ show/NCT00953758.
  • 91
    • 70349783646 scopus 로고    scopus 로고
    • Angew. Chem. Int. Ed. 2009, 48, 2321-2324.
    • (2009) Angew. Chem. Int. Ed. , vol.48 , pp. 2321-2324


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.